[Condensed Consolidated Statement of Profit or Loss and Other Comprehensive Income](index=2&type=section&id=Condensed%20Consolidated%20Statement%20of%20Profit%20or%20Loss%20and%20Other%20Comprehensive%20Income) The company reported a significant reduction in losses across all key metrics, driven by revenue growth and a shift from gross loss to gross profit Condensed Consolidated Statement of Profit or Loss and Other Comprehensive Income Summary | Metric | 2025 (HKD thousands) | 2024 (HKD thousands) | Change (%) | | :--- | :--- | :--- | :--- | | Revenue | 38,872 | 32,449 | +19.8% | | Gross Profit/(Loss) | 2,542 | (3,107) | Turned from loss to profit | | Operating Loss | (19,308) | (124,588) | Loss narrowed by 84.5% | | Loss Before Tax | (37,159) | (126,258) | Loss narrowed by 70.6% | | Loss for the Period | (36,753) | (125,731) | Loss narrowed by 70.8% | | Loss Attributable to Owners of the Company | (32,006) | (79,917) | Loss narrowed by 60.0% | | Basic and Diluted Loss Per Share (HKD) | (0.033) | (0.083) | Loss narrowed by 60.2% | [Condensed Consolidated Statement of Financial Position](index=4&type=section&id=Condensed%20Consolidated%20Statement%20of%20Financial%20Position) The company's total assets increased slightly, while current assets decreased and total liabilities rose, leading to a decline in total equity Condensed Consolidated Statement of Financial Position Summary | Metric | June 30, 2025 (HKD thousands) | December 31, 2024 (HKD thousands) | Change (%) | | :--- | :--- | :--- | :--- | | Total Assets | 538,426 | 529,955 | +1.6% | | Total Non-Current Assets | 502,598 | 466,860 | +7.6% | | Total Current Assets | 35,828 | 63,095 | -43.2% | | Total Equity | 211,886 | 242,388 | -12.6% | | Total Liabilities | 326,540 | 287,567 | +13.5% | | Total Non-Current Liabilities | 130,849 | 94,953 | +37.8% | | Total Current Liabilities | 195,691 | 192,614 | +1.6% | - Property, plant and equipment increased to **HKD 248,508 thousand** (December 31, 2024: **HKD 219,341 thousand**), primarily due to additions to construction in progress[5](index=5&type=chunk) - Bank and cash balances decreased to **HKD 11,290 thousand** (December 31, 2024: **HKD 18,913 thousand**), reflecting the use of funds for operations and the construction of the BNCT center[5](index=5&type=chunk) [Notes to the Condensed Consolidated Financial Statements](index=6&type=section&id=Notes%20to%20the%20Condensed%20Consolidated%20Financial%20Statements) The notes provide detailed explanations of the Group's business, accounting policies, and financial performance, highlighting going concern uncertainties and mitigation efforts [1. General Information](index=6&type=section&id=1.%20General%20Information) The company is a GEM-listed entity with diverse healthcare businesses in Hong Kong and mainland China, including medical testing, immunotherapy, and BNCT services - The company's main businesses include medical laboratory testing, health checks, and insurance brokerage services in Hong Kong, as well as oncology immune cell therapy, health management, BNCT services, and sales of healthcare pharmaceutical products in mainland China[7](index=7&type=chunk) - The company is listed on GEM of The Stock Exchange of Hong Kong Limited[8](index=8&type=chunk) [2. Basis of Preparation and Accounting Policies](index=6&type=section&id=2.%20Basis%20of%20Preparation%20and%20Accounting%20Policies) The interim financial information is prepared under HKAS 34, with significant going concern uncertainties due to losses and current liabilities exceeding current assets, addressed by cost control and financing efforts - For the six months ended **June 30, 2025**, the Group recorded a loss of approximately **36,753 thousand HKD**, with current liabilities exceeding current assets by approximately **159,863 thousand HKD**, indicating significant uncertainty about its ability to continue as a going concern[11](index=11&type=chunk) - To alleviate liquidity pressure, the Group is implementing operational plans to control costs, optimize resource allocation, reduce staff costs, and actively seeking alternative financing, borrowings, and fundraising solutions (such as placing shares and issuing convertible bonds)[13](index=13&type=chunk) - The Group is exploring the realization of financial assets measured at fair value through other comprehensive income to support operations and growth[13](index=13&type=chunk) [3. Revenue](index=8&type=section&id=3.%20Revenue) The Group's revenue increased by **19.8%**, primarily driven by a substantial rise in insurance brokerage services, partially offset by a decline in medical laboratory testing and health check services Segment Revenue by Service Category | Service Category | 2025 (HKD thousands) | 2024 (HKD thousands) | Y-o-Y Change (%) | | :--- | :--- | :--- | :--- | | Medical Laboratory Testing and Health Check Services | 16,164 | 19,729 | -18.1% | | Insurance Brokerage Services | 22,640 | 12,255 | +84.7% | | Sales and Distribution of Healthcare-related and Pharmaceutical Products and Other Services | – | 437 | -100% | | Logistics Services | 68 | 28 | +142.9% | | **Total Revenue** | **38,872** | **32,449** | **+19.8%** | [4. Segment Information](index=8&type=section&id=4.%20Segment%20Information) The Group operates six segments, with significant growth in insurance brokerage and BNCT profitability, with capital expenditure focused on BNCT and medical/healthcare and immunotherapy segments remain in loss Segment Revenue and (Loss)/Profit **Segment Revenue (For the six months ended June 30):** | Segment | 2025 (HKD thousands) | 2024 (HKD thousands) | | :--- | :--- | :--- | | Medical Laboratory Testing and Healthcare-related Services | 16,164 | 19,729 | | Insurance Brokerage | 22,640 | 12,255 | | Pharmaceutical Products | – | 437 | | Other | 68 | 28 | | **Total** | **38,872** | **32,449** | **Segment (Loss)/Profit (For the six months ended June 30):** | Segment | 2025 (HKD thousands) | 2024 (HKD thousands) | | :--- | :--- | :--- | | Medical Laboratory Testing and Healthcare-related Services | (14,788) | (71,707) | | Immunotherapy | (13,118) | (25,206) | | Boron Neutron Capture Therapy | 8,776 | (3,147) | | Insurance Brokerage | 1,870 | (62) | | Pharmaceutical Products | (720) | (485) | | Other | (340) | (342) | | **Total** | **(18,320)** | **(100,949)** | - Total capital expenditure in **2025** amounted to **22,700 thousand HKD**, with **22,692 thousand HKD** allocated to Boron Neutron Capture Therapy[21](index=21&type=chunk) - Impairment loss on right-of-use assets in **2025** was **3,524 thousand HKD**[21](index=21&type=chunk) [5. Other Income and Gains/(Losses), Net](index=12&type=section&id=5.%20Other%20Income%20and%20Gains%2F%28Losses%29%2C%20Net) Net other income and gains for the period significantly turned from a loss in **2024** to a gain, primarily due to storm damage compensation and exchange gains Other Income and Gains/(Losses), Net | Item | 2025 (HKD thousands) | 2024 (HKD thousands) | | :--- | :--- | :--- | | Compensation Income | 13,695 | – | | Exchange Gains/(Losses), Net | 6,576 | (12,504) | | Loss on Derecognition of Property, Plant and Equipment | – | (15,901) | | **Total** | **21,728** | **(26,460)** | - Compensation income of **13,695 thousand HKD** relates to insurance claims for storm damage at a Hainan construction site in **2024**[23](index=23&type=chunk) [6. Finance Costs](index=12&type=section&id=6.%20Finance%20Costs) Finance costs substantially increased due to higher interest on convertible bonds, put option liabilities, and other borrowings Finance Costs Breakdown | Item | 2025 (HKD thousands) | 2024 (HKD thousands) | | :--- | :--- | :--- | | Interest on Bank Borrowings | 523 | 814 | | Interest on Other Borrowings | 4,191 | 1,115 | | Interest on Loans from Controlling Shareholder | 1,291 | 205 | | Interest on Convertible Bonds and Put Option Liabilities | 6,294 | 2,158 | | Interest on Lease Liabilities | 237 | 394 | | **Total** | **12,536** | **4,686** | [7. Loss Before Tax](index=13&type=section&id=7.%20Loss%20Before%20Tax) Loss before tax significantly narrowed, driven by reduced research and development, staff costs, and inventory write-downs, partially offset by impairment loss on right-of-use assets Loss Before Tax Components | Item | 2025 (HKD thousands) | 2024 (HKD thousands) | | :--- | :--- | :--- | | Research and Development Costs | 5,965 | 17,593 | | Staff Costs (Salaries, Bonuses and Allowances) | 25,021 | 38,985 | | Write-down of Inventories | 194 | 5,089 | | Derecognition of Property, Plant and Equipment | – | 15,901 | | Impairment Loss on Right-of-Use Assets | 3,524 | – | [8. Income Tax Credit](index=13&type=section&id=8.%20Income%20Tax%20Credit) Income tax credit for the period was slightly lower than the prior year, primarily derived from deferred income tax Income Tax Credit Breakdown | Item | 2025 (HKD thousands) | 2024 (HKD thousands) | | :--- | :--- | :--- | | Current Income Tax | (195) | (78) | | Deferred Income Tax | 601 | 605 | | **Total** | **406** | **527** | [9. Dividends](index=14&type=section&id=9.%20Dividends) The Board does not recommend any dividend payment for the current interim period, consistent with the prior year - The Board does not recommend the payment of any dividend for the period[27](index=27&type=chunk) [10. Loss Per Share](index=14&type=section&id=10.%20Loss%20Per%20Share) Basic and diluted loss per share attributable to owners of the Company significantly improved, reflecting a reduction in per-share losses Basic and Diluted Loss Per Share | Metric | 2025 (HKD) | 2024 (HKD) | | :--- | :--- | :--- | | Basic and Diluted Loss Per Share | (0.033) | (0.083) | - The weighted average number of ordinary shares used for calculating basic and diluted loss per share increased from **963,231 thousand** in **2024** to **975,731 thousand** in **2025**[29](index=29&type=chunk) [11. Property, Plant and Equipment](index=14&type=section&id=11.%20Property%2C%20Plant%20and%20Equipment) The primary addition to property, plant and equipment for the period was significant investment in construction in progress - Main addition was **22,692 thousand HKD** for construction in progress[30](index=30&type=chunk) [12. Goodwill](index=15&type=section&id=12.%20Goodwill) The carrying amount of goodwill increased, primarily influenced by exchange differences during the period Goodwill Carrying Amount | Metric | June 30, 2025 (HKD thousands) | June 30, 2024 (HKD thousands) | | :--- | :--- | :--- | | Carrying Amount | 107,225 | 104,792 | | Exchange Differences | 3,331 | (2,389) | [13. Intangible Assets](index=15&type=section&id=13.%20Intangible%20Assets) The net carrying amount of intangible assets decreased, mainly due to amortisation expense, partially offset by exchange differences Intangible Assets Net Carrying Amount | Metric | June 30, 2025 (HKD thousands) | June 30, 2024 (HKD thousands) | | :--- | :--- | :--- | | Net Carrying Amount at End of Period | 32,013 | 52,623 | | Amortisation Expense | (4,005) | (4,036) | | Exchange Differences | 1,074 | (985) | [14. Trade and Other Receivables, Deposits and Prepayments](index=16&type=section&id=14.%20Trade%20and%20Other%20Receivables%2C%20Deposits%20and%20Prepayments) Net trade receivables increased, with a significant portion of deposits allocated to purchasing BNCT drugs from a Japanese pharmaceutical company Trade and Other Receivables, Deposits and Prepayments | Item | June 30, 2025 (HKD thousands) | December 31, 2024 (HKD thousands) | | :--- | :--- | :--- | | Net Trade Receivables | 7,988 | 7,033 | | Rental and Other Deposits | 56,799 | 51,822 | | Other Receivables | 8,246 | 14,012 | | Prepayments | 3,490 | 1,991 | | **Total** | **76,547** | **74,872** | - Rental and other deposits include **54,559 thousand HKD** (equivalent to **1,000,000,000 JPY**) as a deposit paid to a Japanese pharmaceutical company for Boron Neutron Capture Therapy drugs to be used at the Hainan BNCT Cancer Treatment Centre[32](index=32&type=chunk) [15. Trade Payables](index=17&type=section&id=15.%20Trade%20Payables) Total trade payables increased as of **June 30, 2025**, compared to **December 31, 2024** Trade Payables Ageing Analysis | Ageing | June 30, 2025 (HKD thousands) | December 31, 2024 (HKD thousands) | | :--- | :--- | :--- | | 0 to 90 days | 4,440 | 4,883 | | 91 to 180 days | 1,278 | 1,549 | | 181 to 365 days | 1,610 | 166 | | Over 365 days | 770 | 755 | | **Total** | **8,098** | **7,353** | [16. Convertible Bonds and Derivative Financial Liabilities](index=17&type=section&id=16.%20Convertible%20Bonds%20and%20Derivative%20Financial%20Liabilities) The Group's convertible bonds and related derivative financial liabilities, including written put option liabilities, saw increases in their fair values - In **December 2024**, convertible bonds with a principal amount of **6,000,000 USD** (approximately **47,100 thousand HKD**) were issued at an annual interest rate of **8.25%** and an initial conversion price of **1.20 HKD** per share[35](index=35&type=chunk) Convertible Bonds and Derivative Financial Liabilities | Item | June 30, 2025 | December 31, 2024 | | :--- | :--- | :--- | | Convertible Bonds - Liability Component | 42,919 | 41,635 | | Convertible Bonds - Fair Value of Derivative Component | 11,317 | 6,002 | | Written Put Option Liabilities | 45,065 | 40,480 | - The effective interest rate applied to the convertible bonds' liability component was **15.0%** (**2024**: **8.62%**)[36](index=36&type=chunk) [17. Borrowings](index=19&type=section&id=17.%20Borrowings) Total borrowings increased, primarily for working capital and BNCT center development, secured by various assets, with the Group complying with all financial covenants Total Borrowings and Analysis **Total Borrowings (HKD thousands):** | Item | June 30, 2025 | December 31, 2024 | | :--- | :--- | :--- | | Bank Borrowings | 33,981 | 25,981 | | Other Borrowings | 99,041 | 87,940 | | Loans from Controlling Shareholder | 28,074 | 24,772 | | **Total** | **161,096** | **138,693** | **Borrowings Analysis (HKD thousands):** | Item | June 30, 2025 | December 31, 2024 | | :--- | :--- | :--- | | Current Portion | 139,179 | 138,693 | | Non-Current Portion | 21,917 | – | - Borrowing interest rates range from **LPR minus 0.45% or 3.45%–3.85%** for bank borrowings, **6%–18%** for other borrowings, and **10%** for controlling shareholder loans[39](index=39&type=chunk) - Borrowings are primarily secured by construction in progress (**233,866 thousand HKD**), China land use rights (**11,799 thousand HKD**), property, plant and equipment (**10,743 thousand HKD**), other receivables (**1,864 thousand HKD**), intangible assets (**30,689 thousand HKD**), and a **47%** equity interest in a subsidiary[40](index=40&type=chunk)[41](index=41&type=chunk) - The Group has complied with the financial covenants of its borrowing facilities[42](index=42&type=chunk) [18. Contingent Liabilities](index=20&type=section&id=18.%20Contingent%20Liabilities) The Group reported no material contingent liabilities as of **June 30, 2025** - The Group had no material contingent liabilities[43](index=43&type=chunk) [19. Related Party Transactions](index=20&type=section&id=19.%20Related%20Party%20Transactions) Related party transactions for the period primarily included interest expenses paid to the controlling shareholder and key management personnel remuneration Related Party Transactions Summary | Item | 2025 (HKD thousands) | 2024 (HKD thousands) | | :--- | :--- | :--- | | Interest Expenses Paid to Controlling Shareholder | 1,291 | 205 | | Key Management Personnel Remuneration | 2,589 | 3,615 | [20. Events After Reporting Period](index=21&type=section&id=20.%20Events%20After%20Reporting%20Period) Post-reporting period events include a strategic financing agreement where BGI-Songhe will provide a loan to Pengbo (Hainan), convertible into Dynamic Healthcare shares - BGI-Songhe will provide a **30 million RMB** loan to Pengbo (Hainan), which will be converted into shares of Dynamic Healthcare Holdings Limited[46](index=46&type=chunk) - BGI-Songhe will hold up to **6.25%** of Dynamic Healthcare's enlarged issued share capital[46](index=46&type=chunk) [Financial Review](index=22&type=section&id=Financial%20Review) The financial review highlights a significant reduction in net loss, improved gross margin, and reduced operating expenses, despite increased finance costs - Revenue for the period was approximately **38.9 million HKD**, an increase of **19.8%** year-on-year, primarily driven by growth in the insurance brokerage services segment, partially offset by a decline in the medical laboratory testing and health check services segment[48](index=48&type=chunk) - Gross profit turned from a loss of approximately **3.1 million HKD** in the prior year to a profit of approximately **2.5 million HKD**, with gross margin improving to **6.5%**, mainly due to a significant reduction in inventory write-downs[49](index=49&type=chunk) - Selling and distribution expenses decreased by **44.6%** to **3.6 million HKD**, administrative expenses decreased by **52.0%** to **34.0 million HKD**, and research and development costs decreased by **66.1%** to **6.0 million HKD**, primarily due to reduced staff costs, fewer one-off legal claims, and lower late-stage clinical trial expenses[50](index=50&type=chunk)[51](index=51&type=chunk)[52](index=52&type=chunk) - Finance costs increased to **12.5 million HKD**, mainly due to additional bank and other borrowings for working capital and the construction of the BNCT Cancer Treatment Centre[53](index=53&type=chunk) - Net loss attributable to owners of the Company decreased by **60.0%** to **32.0 million HKD**, primarily due to cost control measures, improved gross margin, reduced administrative expenses, and **13.7 million HKD** in insurance compensation income[54](index=54&type=chunk) [Business Review](index=24&type=section&id=Business%20Review) The business review covers strategic financing, progress on the BNCT center, expanded drug cooperation, new insurance products, and advancements in CAR-T clinical trials - Pengbo (Hainan) secured **30 million RMB** in strategic financing from BGI-Songhe to strengthen its development foundation[55](index=55&type=chunk) - The BNCT Cancer Treatment Centre is under construction in Hainan, targeting opening and operation by **end of 2025**, having obtained medical institution practice license and medical device import approval[57](index=57&type=chunk) - Signed an MOU with STELLA PHARMA CORPORATION to expand cooperation for BNCT drug STEBORONINE® in China, including exclusive manufacturing and sales rights, with plans for localized production[58](index=58&type=chunk) - Collaborated with AXA Insurance (Bermuda) Limited to develop comprehensive medical insurance products covering BNCT cancer treatment costs and related services[59](index=59&type=chunk) - Shanghai Longyao's LY007 cell injection (China's first clinically approved CD20-targeted CAR-T therapy) has completed Phase I clinical trials, with Phase II trials planned to commence by **end of 2025**[61](index=61&type=chunk) - Phase I clinical results for LY007 cell injection have been presented at international conferences like ASCO and ASH, and invited for presentation at ICML and EHA[64](index=64&type=chunk) [Outlook](index=27&type=section&id=Outlook) The Group's outlook focuses on laboratory upgrades, expanding healthcare services, commercializing CAR-T products, operationalizing the BNCT center, and developing integrated treatment models and insurance products - The Group has upgraded its laboratory with Hong Kong's first customized virtual biochemistry immunoassay automation system, collaborating with institutions for contract research services and public health screening/vaccination programs[66](index=66&type=chunk) - Demand for health checks and related medical services is expected to continue growing due to increased public health awareness, an aging population, and rising demand for private healthcare services[67](index=67&type=chunk) - The Group aims to advance the commercialization of its CAR-T product LY007 cell injection, pushing for domestic Phase II clinical trials and commercial partnerships, including international patenting, with Phase II trials expected to start by **end of 2025**[68](index=68&type=chunk) - The Group is committed to ensuring the BNCT Cancer Treatment Centre is operational by **end of 2025**, planning a China-wide treatment network, developing franchised hospitals, and generating new revenue from equipment sales and related services[69](index=69&type=chunk) - Deepen industry-academic research integration with leading hospitals to explore a new "diagnosis-treatment integrated" BNCT model[70](index=70&type=chunk) - Strengthen cooperation with insurance companies to develop inclusive BNCT medical insurance products and establish patient referral partnerships with domestic hospitals to enhance accessibility and reduce financial burden[71](index=71&type=chunk) [Events After Reporting Period](index=29&type=section&id=Events%20After%20Reporting%20Period) Details of events after the reporting period are set out in Note 20 to the unaudited condensed consolidated financial statements - Details of events after the reporting period are set out in Note 20 to the unaudited condensed consolidated financial statements[73](index=73&type=chunk) [Liquidity, Financial Resources and Capital Structure](index=30&type=section&id=Liquidity%2C%20Financial%20Resources%20and%20Capital%20Structure) The Group's liquidity shows decreased cash balances and increased borrowings, with capital commitments for property, plant and equipment, and secured loans - Cash and bank balances decreased to **11,290 thousand HKD** (December 31, 2024: **18,913 thousand HKD**), primarily used for operating activities and the construction of the BNCT Cancer Treatment Centre[75](index=75&type=chunk) - Outstanding convertible bonds amounted to approximately **42,919 thousand HKD**, with an annual interest rate of **8.25%**, maturing on **December 27, 2026**[75](index=75&type=chunk) - Total borrowings increased to **161,096 thousand HKD** (December 31, 2024: **138,693 thousand HKD**), mainly due to additional borrowings for working capital and the development of the BNCT Cancer Treatment Centre[76](index=76&type=chunk) Financial Ratios | Metric | June 30, 2025 | December 31, 2024 | | :--- | :--- | :--- | | Debt-to-Equity Ratio | 60.6% | 54.3% | | Current Ratio | **0.18 times** | **0.33 times** | - Capital commitments for property, plant and equipment increased to **153,210 thousand HKD** (December 31, 2024: **122,560 thousand HKD**)[79](index=79&type=chunk) - Borrowings are secured by Pengbo (Hainan)'s land use rights, construction in progress, property, plant and equipment, other receivables, intangible assets, and equity interest in a subsidiary[80](index=80&type=chunk)[81](index=81&type=chunk) - The Group has no material contingent liabilities and uses hedging instruments to manage foreign exchange and interest rate risks[82](index=82&type=chunk)[83](index=83&type=chunk) [Material Investments Held and Performance](index=33&type=section&id=Material%20Investments%20Held%20and%20Performance) The Group holds significant investments in precision cancer diagnostics companies, with strategic collaborations expected to generate synergies with its medical testing services - The Group holds investments in Pillar Biosciences, Inc and Zhengu Diagnostics Holdings Limited (precision cancer diagnostics companies) with a fair value of approximately **43,703 thousand HKD**, representing **8.12%** of total assets[84](index=84&type=chunk) - Pillar Biosciences, Inc recorded an unaudited loss of approximately **17,000,000 USD** in **2024**, and the Group received no dividend income from Pillar during the period[85](index=85&type=chunk) - Strategic cooperation with Pillar led to the establishment of Asia Molecular Diagnostics Laboratory Limited in Hong Kong, offering next-generation sequencing precision cancer diagnostic services, expected to generate synergies with the Group's medical testing services[85](index=85&type=chunk) [Material Acquisitions and Disposals of Subsidiaries and Associates](index=34&type=section&id=Material%20Acquisitions%20and%20Disposals%20of%20Subsidiaries%20and%20Associates) The Group did not engage in any material acquisitions or disposals of subsidiaries and associates during the reporting period - The Group did not undertake any material acquisitions or disposals of subsidiaries and associates during the period[86](index=86&type=chunk) [Employees and Remuneration Policy](index=34&type=section&id=Employees%20and%20Remuneration%20Policy) The Group's employee count slightly decreased, with remuneration policies based on performance, experience, and market rates, including various benefits and incentive schemes - As of **June 30, 2025**, the Group employed **133** full-time employees (**June 30, 2024**: **142**)[87](index=87&type=chunk) - Remuneration is determined based on performance, experience, and market rates, including discretionary bonuses, MPF scheme, retirement benefit scheme contributions, insurance and medical, training, and participation in share option and share award schemes[87](index=87&type=chunk) [Share Option Scheme](index=34&type=section&id=Share%20Option%20Scheme) The company adopted a share option scheme in **2024**, but no options were granted during the current reporting period - The company adopted a share option scheme on **June 6, 2024**, but no share options were granted during the period[88](index=88&type=chunk) [Share Award Scheme](index=34&type=section&id=Share%20Award%20Scheme) The company adopted a share award scheme in **2021**, but no shares were subscribed for, received, purchased, or granted under the scheme during the current period - The company adopted a share award scheme on **August 18, 2021**, but the trustee neither subscribed for, received, nor purchased any company shares, nor did the company grant any shares under the scheme during the period[89](index=89&type=chunk) [Directors' Rights to Acquire Shares or Debentures](index=35&

董事會會議通告 中國生物科技服務控股有限公司（「本公司」）董事（「董事」）會（「董事會」） 謹此宣佈將於二零二五年八月二十七日（星期三）舉行董事會會議，以（其中 包括）考慮及批准本公司及其附屬公司截至二零二五年六月三十日止六個月之 未經審核簡明綜合中期業績，並考慮派付股息（如有）。 承董事會命 中國生物科技服務控股有限公司 主席兼執行董事 劉小林 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對 其準確性或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部分內 容而產生或因倚賴該等內容而引致之任何損失承擔任何責任。 香港，二零二五年八月十五日 於本公告日期，董事會包括四名執行董事，即劉小林先生（主席）、何詢先生、黃嵩先 生及尹燁博士；及三名獨立非執行董事，即鄢國祥先生、郭圓濤博士及張曉博士。 本公告的資料乃遵照 GEM 上市規則而刊載，旨在提供有關本公司的資料；董事願就本 公告的資料共同及個別地承擔全部責任。各董事在作出一切合理查詢後，確認就其所 知及所信，本公告所載資料在各重要方面均屬準確完備，沒有誤導或欺詐成分，且並 無遺漏任何事項，足以令致本公告或其所載任何陳述產生誤 ...

Core Viewpoint - China Biotechnology Services (08037) expects a significant reduction in losses for the first half of 2025, projecting a loss attributable to shareholders of no more than HKD 33 million, which is approximately 59% lower than the loss of HKD 79.917 million in the same period of 2024 [1] Group 1 - The improvement in operational performance is primarily attributed to successful cost control measures implemented by the company [1] - The company has experienced an increase in gross margin and a reduction in administrative expenses [1] - The company received compensation income of approximately HKD 14 million from insurance claims related to damages caused by heavy rainfall to construction sites in Hainan during 2024 [1]

Group 1 - The company expects a significant reduction in loss for the first half of 2025, with an estimated loss not exceeding 33 million HKD, compared to a loss of 79.917 million HKD in the same period of 2024, representing a decrease of approximately 59% [1] - The improvement in operational performance is primarily attributed to successful cost control measures, which have led to an increase in gross margin and a reduction in administrative expenses [1] - The company also received compensation income of approximately 14 million HKD from insurance claims related to damages caused by heavy rainfall to construction sites in Hainan during 2024 [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責， 對其準確性或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何 部分內容而產生或因倚賴該等內容而引致之任何損失承擔任何責任。 CHINA BIOTECH SERVICES HOLDINGS LIMITED 中國生物科技服務控股有限公司 （於開曼群島註冊成立並在百慕達繼續營業之有限公司） （股份代號：8037） 盈利預告－虧損減少 本公告乃由中國生物科技服務控股有限公司（「本公司」，連同其附屬公司統稱為「本 集團」）根據香港聯合交易所有限公司GEM證券上市規則（「GEM上市規則」）第 17.10(2)(a)條及香港法例第571章《證券及期貨條例》第XIVA部項下之內幕消息條 文（定義見上市規則）而作出。 本公司董事（「董事」）會（「董事會」）謹此知會本公司股東（「股東」）及潛在投資者， 根據管理層目前可獲得之資料及對本集團截至2025年6月30日止6個月（「2025年中 期期間」）之最新未經審核綜合管理賬目（「管理賬目」）作出的初步審閱及評估，預 計2025年中期期間本公司擁有人應佔虧損將不多於33,000,000港元，較2024 ...

致：香港交易及結算所有限公司 公司名稱: 中國生物科技服務控股有限公司 呈交日期: 2025年8月4日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | | 於香港聯交所上市 (註1) | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 08037 | 說明 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 2,000,000,000 | HKD | | 0.1 HKD | | 200,000,000 | | 增加 / 減少 (-) | | | | | | HKD | | | | 本月底結存 | | | 2,000,000,000 | HKD | | 0.1 HKD | | 200,000,000 | 本月底法定/註冊股本總額： HKD 200,000,000 第 1 頁 共 10 頁 v 1.1.1 FF301 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的 ...

Company Overview - China Biotech Services Holdings Limited (stock code 08037.HK) is listed on the Hong Kong Stock Exchange and is headquartered in Hong Kong [2] - The company aims to create an integrated advanced biotechnology platform for cancer diagnosis and treatment, with business segments including PHC Standard Pathology Laboratory, AMDL Asia Molecular Diagnostics Laboratory, and Vcare Health Management [2] Financial Performance - As of December 31, 2024, the company reported total revenue of 65.2942 million yuan, a year-on-year decrease of 66.74% [1] - The net profit attributable to the parent company was -183 million yuan, a year-on-year decrease of 107.6% [1] - The gross profit margin was -7.01%, and the debt-to-asset ratio was 54.26% [1] Stock Performance - As of July 11, the stock price closed at 0.72 HKD per share, an increase of 10.77% with a trading volume of 765,000 shares and a turnover of 546,600 HKD [1] - Over the past month, the stock has seen a cumulative decline of 14.47%, while it has increased by 27.45% year-to-date, outperforming the Hang Seng Index by 19.78% [1] Industry Valuation - The average price-to-earnings (P/E) ratio for the healthcare equipment and services industry (TTM) is -2.68 times, with a median of 1.17 times [1] - China Biotech Services has a P/E ratio of -3.2 times, ranking 93rd in the industry [1] - Other companies in the industry include Giant Medical Holdings (02393.HK) at 0.28 times, Jingjiu Health (00648.HK) at 0.38 times, Yihui Group (08161.HK) at 1.96 times, Global Medical (02666.HK) at 5.24 times, and Ruici Medical (01526.HK) at 5.4 times [1]

Core Viewpoint - China Biotechnology Services (08037) has entered into a non-binding memorandum of understanding with AXA Group and other partners to jointly develop affordable medical insurance products covering Boron Neutron Capture Therapy (BNCT) treatment costs and related services [1][2][3] Group 1: Collaboration Areas - Patient Medical Services: The company will provide treatment services including surgery, hospitalization, and post-operative rehabilitation for patients covered by insurance who are diagnosed for BNCT treatment at Hainan Pengbo BNCT Treatment Center and potentially other medical networks in the future [1] - Insurance Product Development and Marketing: Based on medical data provided by the company, partners will assist in developing competitive BNCT insurance products and promote them extensively in mainland China, Hong Kong, and potentially overseas markets [1][2] - Reinsurance Solutions: Partners will provide reinsurance solutions for BNCT insurance, leveraging their expertise in risk assessment and management to support pricing and risk control [2] Group 2: Market Expansion - Overseas Market Development: AXA and Gallagher will utilize their global insurance and reinsurance networks to help the company develop BNCT medical insurance products tailored for different countries and collaborate with local insurance companies [2] - Launch of BNCT Insurance in Hong Kong: AXA Hong Kong will be the first insurer to launch BNCT insurance products in the Hong Kong market [2] Group 3: Partner Profiles - AXA Group is a leading global insurance company operating in 50 markets, serving 95 million customers worldwide [3] - Qianhai Reinsurance, established in Shenzhen, is the first state-owned mixed-ownership reinsurance company in China, providing various reinsurance products and services [3] - Gallagher, a leading global insurance brokerage and risk management firm, offers professional insurance solutions and consulting services to clients worldwide [3] Group 4: Strategic Goals - The collaboration aims to develop affordable medical insurance products covering BNCT treatment costs to reduce the financial burden on patients and enhance treatment accessibility [3] - The partnership is expected to create synergies for the company's BNCT business, providing treatment to more patients in China and abroad, highlighting the company's commitment to improving global patient treatment outcomes [3]

Core Viewpoint - China Biotechnology Services (08037) announced that its indirect non-wholly owned subsidiary, Shanghai Longyao Biotechnology Co., Ltd., will present the Phase I clinical trial results of LY007 cell injection at two major international conferences in 2025, highlighting its potential to fill the treatment gap in CD20 CAR-T therapy [1] Group 1: Efficacy and Safety - LY007 features a unique OX40 co-stimulation signal design that significantly enhances T cell expansion and anti-tumor activity. Phase I clinical trial data shows that 92% of 12 patients with relapsed/refractory CD20-positive B-cell non-Hodgkin lymphoma experienced tumor reduction or disappearance, with a best complete response rate (BCRR) of 75%. One patient who failed CD19 CAR-T treatment achieved complete remission without severe cytokine release syndrome or neurotoxicity [2] Group 2: Differentiated Indication Strategy - LY007 offers a new treatment option for patients who failed CD19 CAR-T therapy or are CD19-negative relapsed. The CAR-T cells peaked at 46% to 80% of CD3+ T cells in patients. Shanghai Longyao plans to further promote international multicenter clinical research for LY007 at the International Conference on Malignant Lymphoma and the European Hematology Association meeting, exploring collaborations with European and American institutions. The company has laid out 14 global patents to support product commercialization and expansion into solid tumor indications. Over the past year, the Phase I clinical research results of LY007 have been presented at major global oncology and hematology conferences, indicating recognition and attention in the global academic field [3]

智通财经APP讯，中国生物科技服务(08037)发布公告，关于上海银行浦东分行(贷款人)向本公司的间接 非全资附属公司上海隆耀生物科技有限公司(上海隆耀)提供为期一年的银行授信。贷款人同意续订银行 授信，上海隆耀与贷款人订立小企业流动资金借款合同(借款合同)。根据借款合同，贷款人同意向上海 隆耀提供本金最多为人民币400万元的信贷额度，自借款合同日期起为期一年，以供用作一般流动资金 用途。 作为根据借款合同提供信贷额度的代价，本公司及本公司的主席、执行董事兼控股股东刘小林先生(刘 先生)各自订立以贷款人为受益人的普惠及小企业借款保证合同(统称"保证合同")，以无条件及不可撤回 的保证妥为及准时履行借款合同的义务，包括上海隆耀据此支付所有到期及应付款项。实际义务由保证 合同的条款管限。 本公司及刘先生以上海市中小微企业政策性融资担保基金管理中心(借款合同的另一名保证人)(该中心) 为受益人，分别签立《不可撤销信用反担保函》及《个人无限连带责任保证函》(统称"反担保函")，为 该中心提供反担保。根据反担保函，本公司及刘先生为该中心提供无限连带责任反担保。反担保的具体 范围、条款及年期由反担保函管限。 借款合同、保 ...